Dr. Luis J. Haddock, M.D.
Ophthalmology (Ophthalmology Physician)
- Medicare participating
At a glance
- Medical school
- University of Puerto Rico School of Medicine (2008)
- Years since graduation
- 18
- In the NPI registry since
- 2008
- Medicare patients seen, 2024
- 1,498
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2008Medical school: University of Puerto Rico School of Medicine
- 2008Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Ophthalmology Physician primary
FL license ME120731
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Medical groups
- University of Miami (2,377 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 1,498
- Services billed
- 30,429
- Patients’ average age
- 77
| Service | Times | Patients |
|---|---|---|
| Injection, faricimab-svoa, 0.1 mg | 15,900 | 56 |
| Imaging of retina | 1,903 | 869 |
| Injection, aflibercept, 1 mg | 1,292 | 173 |
| Established patient office or other outpatient visit, 30-39 minutes | 1,189 | 435 |
| Injection of drug into eye | 1,174 | 344 |
| Established patient complete exam of visual system | 1,065 | 849 |
| Photography of the retina | 942 | 724 |
| Injection, pegcetacoplan, intravitreal, 1 mg | 660 | 16 |
| Established patient office or other outpatient visit, 20-29 minutes | 365 | 259 |
| Unclassified drugs | 334 | 101 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Prednisolone Acetate Other prescribers in Palm Beach Gardens, FL | 235 |
| Ketorolac Tromethamine Other prescribers in Palm Beach Gardens, FL | 114 |
| Latanoprost Other prescribers in Palm Beach Gardens, FL | 74 |
| Dorzolamide-Timolol (dorzolamide hcl/timolol maleat) Other prescribers in Palm Beach Gardens, FL | 65 |
| Brimonidine Tartrate Other prescribers in Palm Beach Gardens, FL | 41 |
| Polymyxin B Sul-Trimethoprim (polymyxin b sulf/trimethoprim) | 40 |
| Timolol Maleate Other prescribers in Palm Beach Gardens, FL | 26 |
| Dorzolamide Hcl Other prescribers in Palm Beach Gardens, FL | 23 |
| Restasis (cyclosporine) Other prescribers in Palm Beach Gardens, FL | 17 |
| Atropine Sulfate | 12 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 10 companies reported 27 payments worth $1,093 in total to this clinician.
| Regeneron Healthcare Solutions, Inc. | $233 |
|---|---|
| Notal Vision, Inc. | $197 |
| Apellis Pharmaceuticals, Inc. | $169 |
| Alcon Vision LLC | $144 |
| Carl Zeiss Meditec USA, Inc. | $139 |
| Astellas Pharma US Inc | $67.12 |
| AbbVie Inc. | $57.22 |
| Harrow Eye, LLC | $32.94 |
| Food and Beverage | $1,093 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $7,255 in research payments for these studies, mostly to the institutions running them.
- A Phase 2, Double Masked, Placebo Controlled, Dose Range Finding Study of Danicopan (ALXN2040) in Patients with Geographic Atrophy (GA) Secondary to Age Related Macular Degeneration (AMD)
Alexion Pharmaceuticals, Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.